Evidence map›Paper›PMID 32706792›Full record

ArticlePloS one2020

Philanthotoxin-343 attenuates retinal and optic nerve injury, and protects visual function in rats with N-methyl-D-aspartate-induced excitotoxicity.

Muhammad Fattah Fazel, Izuddin Fahmy Abu, Mohamad Haiqal Nizar Mohamad, Renu Agarwal, Igor Iezhitsa, Nor Salmah Bakar, Norsham Juliana, Ian R Mellor, Henrik Franzyk

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Nutraceuticals ofDrug design, development and therapy · 2026
    Review
  3. Review
  4. Article
  5. Glaucoma Animal Models beyond Chronic IOP Increase.International journal of molecular sciences · 2024
    Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 3 countries.

Muhammad Fattah FazelInstitute of Medical Science Technology, Universiti Kuala Lumpur, Kuala Lumpur, Malaysia.
Izuddin Fahmy AbuInstitute of Medical Science Technology, Universiti Kuala Lumpur, Kuala Lumpur, Malaysia.ORCID 0000-0001-6205-001X
Mohamad Haiqal Nizar MohamadInstitute of Medical Science Technology, Universiti Kuala Lumpur, Kuala Lumpur, Malaysia.
Renu AgarwalSchool of Medicine, International Medical University, Bukit Jalil, Kuala Lumpur, Malaysia.
Igor IezhitsaSchool of Medicine, International Medical University, Bukit Jalil, Kuala Lumpur, Malaysia.
Nor Salmah BakarFaculty of Medicine, Universiti Teknologi MARA, Sungai Buloh, Selangor, Malaysia.
Norsham JulianaFaculty of Medicine & Health Sciences, Universiti Sains Islam Malaysia, Indah, Kuala Lumpur, Malaysia.ORCID 0000-0001-8660-5593
Ian R MellorSchool of Life Sciences, Faculty of Medicine & Health Sciences, University of Nottingham, Nottingham, United Kingdom.
Henrik FranzykDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
University of Kuala Lumpur · MYIMU University · MYUniversiti Sains Islam Malaysia · MYUniversiti Teknologi MARA · MYUniversity of Copenhagen · DKUniversity of Nottingham · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Retinal ganglion cell (RGC) loss and optic neuropathy, both hallmarks of glaucoma, have been shown to involve N-methyl-D-aspartate receptor (NMDAR)-mediated excitotoxicity. This study investigated the neuroprotective effects of Philanthotoxin (PhTX)-343 in NMDA-induced retinal injury to alleviate ensuing visual impairments. Sprague-Dawley rats were divided into three; Group I was intravitreally injected with phosphate buffer saline as the control, Group II was injected with NMDA (160 nM) to induce retinal excitotoxic injury, while Group III was injected with PhTX-343 (160 nM) 24 h prior to excitotoxicity induction with NMDA. Rats were subjected to visual behaviour tests seven days post-treatment and subsequently euthanized. Rat retinas and optic nerves were subjected to H&E and toluidine blue staining, respectively. Histological assessments showed that NMDA exposure resulted in significant loss of retinal cell nuclei and thinning of ganglion cell layer (GCL). PhTX-343 pre-treatment prevented NMDA-induced changes where the RGC layer morphology is similar to the control. The numbers of nuclei in the NMDA group were markedly lower compared to the control (p<0.05). PhTX-343 group had significantly higher numbers of nuclei within 100 μm length and 100 μm2 area of GCL (2.9- and 1.7-fold, respectively) compared to NMDA group (p<0.05). PhTX-343 group also displayed lesser optic nerve fibres degeneration compared to NMDA group which showed vacuolation in all sections. In the visual behaviour test, the NMDA group recorded higher total distance travelled, and lower total immobile time and episodes compared to the control and PhTX-343 groups (p<0.05). Object recognition tests showed that the rats in PhTX-343 group could recognize objects better, whereas the same objects were identified as novel by NMDA rats despite multiple exposures (p<0.05). Visual performances in the PhTX-343 group were all comparable with the control (p>0.05). These findings suggested that PhTX-343 inhibit retinal cell loss, optic nerve damage, and visual impairments in NMDA-induced rats.

Indexed as

Neuroprotective AgentsPhenolsPolyaminesAnimalsMaleN-MethylaspartateOptic NerveOptic Nerve InjuriesRatsRats, Sprague-DawleyRetinal Ganglion CellsVision, OcularNeuroprotective AgentsN-MethylaspartatePhenolsphilanthotoxin 343Polyamines

Identifiers

PMID32706792
PMCPMC7380593
OpenAlexW3045485252

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.